natgillin/translations-raw huggingface dataset:
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 brugere): Svimmelhed. 
Common side effects (may affect up to 1 in 10 people): Dizziness.
- klasse Ia-antiarytmika, (f.eks. quinidin, hydroquinidin, disopyramid) - klasse III-antiarytmika, (f.eks. amiodaron, sotalol, doftilid, ibutilid) - visse antipsykotika (f.eks. thioridazin, chlorpromazin, levomepromazin, trifluoperazin, 
- class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide) - class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide) - some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine,
Samtidig indgift af thiazid kan øge forekomsten af overfølsomhedsreaktioner over for allopurinol. 
Co-administration of thiazide may increase the incidence of hypersensitivity reactions of allopurinol.
Hvis disse stoffer gives sammen med hydrochlorthiazid-telmisartan-kombinationen, tilrådes monitorering af kaliumplasmaniveauet. 
If these substances are to be prescribed with the hydrochlorothiazide-telmisartan combination, monitoring of potassium plasma levels is advised.
Blistekort (OPA/Al/PVC folie//Al folie): 14 x 1 tablet 
Blister (OPA/Al/PVC foil//Al foil): 14 x 1 tablet
Infektion i øvre luftveje, urinvejsinfektion herunder cystitis 
Uncommon: Upper respiratory tract infection, urinary tract infection including cystitis Rare:
Der er ingen klinisk erfaring med brug af Tolucombi til patienter med nedsat leverfunktion. 
There is no clinical experience with Tolucombi in patients with hepatic impairment.
- Telmisartan er en såkaldt angiotensin II-receptorantagonist. 
- Telmisartan belongs to a group of medicines called angiotensin II receptor antagonists.
Povidon (K30) Rød jernoxid (E172) Silica, kolloid vandfri Natriumhydroxid (E524) Natriumstearylfumarat Sorbitol (E420) 
Povidone (K30) Red ferric oxide (E172) Silica, colloidal anhydrous Sodium hydroxide (E524) Sodium stearyl fumarate Sorbitol (E420)
Der sås en klar kumulativ dosis/respons relation, hvad angår både basalcellekarcinom og pladecellekarcinom. 
A clear cumulative dose-response relationship was observed for both BCC and SCC.
Tabellen nedenfor viser de bivirkninger, der forekom hyppigere (p ≤0,05) for telmisartan plus hydrochlorthiazid end for placebo i de kliniske forsøg. 
Adverse reactions reported in all clinical trials and occurring more frequently (p ≤0.05) with telmisartan plus hydrochlorothiazide than with placebo are shown below according to system organ class.
Hydrochlorthiazid 
Hydrochlorothiazide:
Hydroxypropylcellulose Lactosemonohydrat Magnesiumstearat 
Hydroxypropylcellulose Lactose monohydrate Magnesium stearate Mannitol
Blisterkort (OPA/Al/PE folie med tørremiddel//Al folie): 14 x 1 og 98 x 1 tablet i en æske. 
Blisters (OPA/Al/PE foil with desiccant//Al foil): 14 x 1 and 98 x 1 tablet in a box.
Lupus-lignende syndrom, lysfølsomhedsreaktion, kutan vaskulit, toksisk epidermal nekrolyse, erythema multiforme 
Skin and subcutaneous tissue disorders Not known: Lupus-like syndrome, photosensitivity reactions, skin vasculitis, toxic epidermal necrolysis, erythema multiforme
I prækliniske studier blev der ikke påvist nedsat fertilitet hos hunner eller hanner ved brug af telmisartan og hydrochlorothiazid. 
In preclinical studies, no effects of telmisartan and hydrochlorothiazide on male and female fertility were observed.
Intravaskulær hypovolæmi Specielt efter første dosis kan der forekomme symptomatisk hypotension hos patienter, som har for lavt volumen i blodbanen eller natriummangel på grund af kraftig diuretisk behandling, saltfattig diæt, diarré eller opkastning. 
Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting.
Dette gælder specielt, hvis du samtidig med Tolucombi tager én af de typer medicin, der er angivet herunder: 
This applies especially to the medicines listed below taken at the same time with Tolucombi:
Forhøjede triglycerider 
Investigations Not known: Triglycerides increased
I en samlet analyse af to ens 8 ugers dobbeltblinde placebo-kontrollerede kliniske forsøg, hvor der blev sammenlignet med valsartan/hydrochlorothiazid 160 mg/25 mg (n=2121 patienter evalueret for effekt) blev der påvist en signifikant større sænkning af blodtrykket på 2,2/1,2 mmHg (SBP/DBP) (gennemsnitlig ændring i forhold til baseline for begge parametre) til fordel for telmisartan/hydrochlorothiazid 80 mg/25 mg kombinationen. 
In a pooled analysis of two similar 8 week double-blind placebo-controlled clinical trials vs. valsartan/hydrochlorothiazide 160 mg/25 mg (n=2121 patients evaluated for efficacy) a significantly greater blood pressure lowering effect of 2.2/1.2 mmHg (SBP/DBP) was demonstrated (difference in adjusted mean changes from baseline, respectively) in favour of telmisartan/hydrochlorothiazide 80 mg/25 mg combination.
I et dobbeltblindt kontrolleret klinisk studie (n=687 patienter evalueret for effekt) hos nonrespondenter i forhold til 80 mg/12,5 mg kombinationen, blev der påvist en øget blodtryktssænkende effekt ved behandling med 80 mg/25 mg kombinationen sammenlignet med fortsat behandling med 80 mg/12,5 mg kombinationen på 2,7/1,6 mmHg (SBP/DBP). 
In a double-blind controlled clinical trial (n=687 patients evaluated for efficacy) in non-responders to the 80 mg/12.5 mg combination, an incremental blood pressure lowering effect of the 80 mg/25 mg combination compared to continued treatment with the 80 mg/12.5 mg combination of 2.7/1.6 mmHg (SBP/DBP) was demonstrated (difference in adjusted mean changes from baseline).
Abdominalsmerter, obstipation, dyspepsi, opkastning, gastrit 
Abdominal pain, constipation,dyspepsia, vomiting, gastritis
I randomiserede, kontrollerede forsøg med alt i alt 1471 patienter, var den totale rapporterede forekomst af bivirkninger ved brug af telmisartan/hydrochlorthiazid (835 patienter) sammenlignelig med forekomsten for telmisartan alene (636 patienter). 
The overall incidence of adverse reactions reported with Tolucombi was comparable to those reported with telmisartan alone in randomised controlled trials involving 1471 patients randomised to receive telmisartan plus hydrochlorothiazide (835) or telmisartan alone (636).
Povidon (K30) Silica, kolloid vandfri Natriumhydroxid (E524) Natriumstearylfumarat Sorbitol (E420) Gul jernoxid (E172) 
Povidone (K30) Silica, colloidal anhydrous Sodium hydroxide (E524) Sodium stearyl fumarate Sorbitol (E420) Yellow ferric oxide (E172)
- hvis du har alvorlige leverproblemer, som f.eks. galdeophobning i galdegangene eller problemer med udskillelse af galde fra leveren og galdeblæren. 
- if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from liver and the gall bladder) or any other severe liver disease.
Hver 80 mg/12,5 mg tablet indeholder 114 mg lactose (som monohydrat) og 294,08 mg sorbitol (E420). 
Each 80 mg/12.5 mg tablet contains 114 mg of lactose (as monohydrate) and 294.08 mg sorbitol (E420).
Du bør ikke tage Tolucombi tidligt i graviditeten, og du må ikke tage det, hvis du er mere end 3 måneder henne i graviditeten, da det kan give dit barn alvorlige skader. 
Tolucombi is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Yderligere oplysninger om de enkelte komponenter Tidligere rapporterede bivirkninger for de enkelte indholdsstoffer kan også være potentielle bivirkninger i forbindelse med Tolucombi, selvom de ikke er observeret i kliniske forsøg med dette produkt. 
Adverse reactions previously reported with one of the individual components may be potential adverse reactions with Tolucombi, even if not observed in clinical trials with this product.
Dette lægemiddel indeholder 294,08 mg sorbitol pr. tablet, svarende til 5 mg/kg/dag, hvis kropsvægten er 58,8 kg. 
This medicine contains 294.08 mg sorbitol in each tablet, which is equivalent to 5 mg/kg/day, if the body weight is 58.8 kg.
Blisterkort 
BLISTER
Utilstrækkelig diabetes mellitus kontrol 
Endocrine disorders Not known: Diabetes mellitus inadequate control
Psykiske forstyrrelser Ikke kendt: 
Psychiatric disorders Not known: Restlessness
Eksponering for behandling med AIIRA'er i 2. og 3. trimester vides at inducere føtotoksicitet hos mennesker (nedsat nyrefunktion, oligohydramnios, forsinket kranieossifikation) og neonatal toksicitet (nyresvigt, hypotension, hyperkaliæmi) (se også pkt. 
Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (See section 5.3).
Betablokkere og diazoxid Thiazider kan øge den hyperglykæmiske virkning af betablokkere og diazoxid. 
Beta-blockers and diazoxide The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.
Hos patienter, der kun får hydrochlorthiazid, er der, i tillæg til de bivirkninger, som er nævnt for Tolucombi, set følgende bivirkninger: 
Hydrochlorothiazide In patients taking hydrochlorothiazide alone the following additional side effects have been reported:
Tolucombi må ikke gives til patienter med svært nedsat leverfunktion. 
Tolucombi is not indicated in patients with severe hepatic impairment.
Behandling med AIIRA'er bør ikke initieres under graviditet. 
Angiotensin II receptor antagonists should not be initiated during pregnancy.
Tolucombi findes også i styrkerne 40 mg/12,5 mg og 80 mg/12,5 mg. 
Tolucombi is also available at the dose strengths 40 mg/12.5 mg and 80 mg/12.5 mg.
- Medicin, der indeholder lithium til behandling af visse typer af depression - Medicin, der kan forårsage lavt kaliumindhold i blodet (hypokaliæmi). 
- Lithium containing medicines to treat some types of depression.
Der er intet, der tyder på, at Tolucombi kan reducere eller forhindre diuretika-forårsaget hyponatriæmi. 
- Hyponatraemia and hypochloraemic alkalosis There is no evidence that Tolucombi would reduce or prevent diuretic-induced hyponatraemia.
Tolucombi bør ikke gives til patienter med kolestase, biliære obstruktive sygdomme eller svær leverinsufficiens (se pkt. 
Tolucombi should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile.
Blisterkort (OPA/Al/PE folie med tørremiddel//Al folie): 14 x 1 tablet 
Blister (OPA/Al/PE foil with desiccant//Al foil): 14 x 1 tablet
Nedenstående bivirkninger, der er blevet rapporteret for de to aktive indholdsstoffer, er også mulige bivirkninger for Tolucombi, selvom de ikke er set i kliniske studier med dette lægemiddel. 
Adverse reactions reported with one of the individual components may be potential adverse reactions with Tolucombi, even if not observed in clinical trials with this product.
Dosisjustering af urikosuriske midler kan være nødvendig, idet hydrochlorthiazid kan øge serumurinsyre. 
Medicinal products used in the treatment for gout (e.g. probenecid, sulfinpyrazone and allopurinol) Dosage adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Hjælpestof(fer), som behandleren skal være opmærksom på Hver tablet indeholder 114 mg lactose (som monohydrat) og 294,08 mg sorbitol (E420). 
Excipient(s) with known effect: Each tablet contains 114 mg of lactose (as monohydrate) and 294.08 mg sorbitol (E420).
Fastdosiskombinationen Tolucombi (40 mg telmisartan/12,5 mg hydrochlorthiazid og 80 mg telmisartan/12,5 mg hydrochlorthiazid) er indiceret til voksne, hvis blodtryk ikke kan reguleres tilfredsstillende med telmisartan alene. 
Tolucombi fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide and 80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.
- Blodtrykssænkende medicin, binyrebarkhormoner (kortikosteroider), smertestillende medicin såsom non-steroide antiinflamatoriske lægemider (NSAID), medicin til behandling af cancer, urinsyregigt (podagra) eller leddegigt. 
- Other medicines used to treat high blood pressure, corticosteroids, painkillers (such as nonsteroidal anti-inflammatory drugs [NSAIDs]), medicines to treat cancer, gout, or arthritis.
Hypotension, ortostatisk hypotension 
Vascular disorders Uncommon: Hypotension, orthostatic hypotension
Betændelse i en spytkirtel, hud- og læbekræft (non-melanom hudkræft), lavt (eller endda manglende) indhold af røde og hvide blodlegemer, alvorlig allergisk reaktion (f.eks. overfølsomhed, anafylaktisk reaktion), appetitløshed, rastløshed, svimmelhed, sløret eller gulligt syn, nedsat syn og øjesmerter (mulige tegn på akut nærsynethed eller akut snævervinklet grøn stær), betændelse i blodkarrene (nekrotiserende vaskulit), betændt bugspytkirtel, maveproblemer, gul i huden eller øjnene (gulsot), lupus-lignende symptomer (bivirkninger, som ligner en sygdom kaldet systemisk lupus erythematosus, hvor kroppens immunsystem angriber kroppen), hudsygdomme som f.eks. betændte blodkar i huden, øget følsomhed for sollys, udslæt, hudrødme, blærer på læber, øjne eller mund, afskalning af hud, feber (mulige tegn på erythema multiforme), svaghed, nyrebetændelse eller nedsat nyrefunktion, sukker i urinen (glykosuri), feber, forstyrrelse i elektrolytbalancen, højt indhold af kolesterol i blodet, nedsat blodvolumen, forhøjet sukkerindhold i blodet, usikkerhed med at kontrollere sukkerindholdet i blod/urin hos patienter med diabetes mellitus eller forhøjet fedtindhold i blodet. 
Inflammation of the salivary gland, skin and lip cancer (Non-melanoma skin cancer), decreases in the number (or even lack) of cells in the blood, including low red and white blood cell count, serious allergic reactions (e.g. hypersensitivity, anaphylactic reaction), decreased or loss of appetite, restlessness, light-headedness, blurred or yellowing of vision, decrease in vision and eye pain (possible signs of acute myopia or acute-angle closure glaucoma), inflammation of blood vessels (vasculitis necrotising), inflamed pancreas, upset stomach, yellowing of the skin or eyes (jaundice), lupus-like syndrome (a condition mimicking a disease called systemic lupus erythematosus where the body's immune system attacks the body); skin disorders such as inflamed blood vessels in the skin, increased sensitivity to sunlight, rash, redness of the skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney inflammation or impaired kidney function, glucose in the urine (glycosuria), fever, impaired electrolyte balance, high blood cholesterol levels, decreased blood volume, increased levels of glucose, difficulties in controlling blood/ urine levels of glucose in patients with a diagnosis of diabetes mellitus, or fat in the blood.
Øre og labyrint Ikke almindelig: 
Ear and labyrinth disorders Uncommon: Vertigo
Hyperurikæmi, hyponatræmi 
Hyperuricaemia, hyponatraemia
Lungebetændelse (bronkitis), provokation eller forværring af systemisk lupus erythematosus (en sygdom, hvor kroppens immunsystem angriber kroppen, hvilket forårsager ledsmerter, hududslæt og feber); ondt i halsen, bihulebetændelse, tristhed (depression), besvær med at falde i søvn (insomni), forringet syn, besvær med at trække vejret, mavesmerter, forstoppelse, oppustethed (dyspepsi), utilpashed (opkastning), mavekatar, unormal leverfunktion (japanske patienter har større sandsynlighed for at få denne bivirkning), rødme af huden, allergiske reaktioner såsom kløe eller udslæt, øget svedproduktion, nældefeber (urticaria), ledsmerter (arthralgi) og smerter i arme og ben, muskelkramper, influenzalignende symptomer, smerter. 
Inflammation of the lung (bronchitis), activation or worsening of systemic lupus erythematosus (a disease where the body's immune system attacks the body, which causes joint pain, skin rashes and fever); sore throat, inflamed sinuses; feeling sad (depression), difficulty falling asleep (insomnia), impaired vision, difficulty breathing, abdominal pain, constipation, bloating (dyspepsia), feeling sick (vomiting), inflammation of the stomach (gastritis), abnormal liver function (Japanese patients are more likely to experience this side effect), redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia) and pain in extremities, muscle cramps, flu-like-illness, pain, low levels of sodium, increased levels of creatinine, hepatic enzymes or creatine phosphokinase in the blood.
- Tolucombi 40 mg/12,5 mg én gang dagligt er til patienter, hvis blodtryk ikke kan reguleres tilfredsstillende med telmisartan 40 mg. 
- Tolucombi 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 40 mg.
Sådan skal du tage Tolucombi 
How to take Tolucombi
Tolucombi (40 mg/12,5 mg, 80 mg/12,5 mg) bruges til at sænke forhøjet blodtryk (essentiel hypertension) hos voksne, hvis blodtryk ikke er sænket tilstrækkeligt med telmisartan. 
Tolucombi (40 mg/12.5 mg, 80 mg/12.5 mg) is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not controlled enough when telmisartan is used alone.
Nedsat kaliumindhold i blodet, angst, besvimelse, snurrende, prikkende og stikkende fornemmelse (paræstesi), følelse af at dreje rundt (svimmelhed), hjertebanken (takykardi), forstyrret hjerterytme, lavt blodtryk, et pludseligt fald i blodtrykket når du rejser dig op, stakåndethed (dyspnø), diaré, mundtørhed, luftafgang fra tarmen, rygsmerter, muskeltrækninger, muskelsmerter, erektil dysfunktion (manglende evne til at få eller opretholde erektion), brystsmerter, forhøjet urinsyreindhold i blodet. 
Decreased blood potassium levels, anxiety, fainting (syncope), sensation of tingling, pins and needles (paraesthesia), feeling of spinning (vertigo), fast heart beat (tachycardia), heart rhythm disorders, low blood pressure, a sudden fall in blood pressure when you stand up, shortness of breath (dyspnoea), diarrhoea, dry mouth, flatulence, back pain, muscle spasm, muscle pain, erectile dysfunction (inability to get or keep an erection), chest pain, increased blood uric acid levels.
Tolucombi 80 mg/12,5 mg og Tolucombi 80 mg/25 mg indeholder 294,08 mg sorbitol pr. tablet, svarende til 5 mg/kg/dag, hvis kropsvægten er 58,8 kg. 
Tolucombi 80 mg/12.5 mg and Tolucombi 80 mg/25 mg contain 294.08 mg sorbitol in each tablet, which is equivalent to 5 mg/kg/day, if the body weight is 58.8 kg.
Luftveje, thorax og mediastinum Ikke almindelig: 
Respiratory, thoracic and mediastinal disorders Uncommon: Dyspnoea Rare:
Blod og lymfesystem Ikke almindelig: 
Blood and lymphatic system disorders Uncommon: Anaemia Rare:
Tolucombi 40 mg/12,5 mg indeholder 147,04 mg sorbitol pr. tablet, svarende til 5 mg/kg/dag, hvis kropsvægten er 29,8 kg. 
Tolucombi 40 mg/12.5 mg contains 147.04 mg sorbitol in each tablet, which is equivalent to 5 mg/kg/day, if the body weight is 29.8 kg.
Sepsis* (ofte kaldet "blodforgiftning", en alvorlig infektion med betændelsesreaktion i hele kroppen), hurtig hævelse af hud og slimhinder (angioødem), blærer og afskalning af det øverste lag af huden (toksisk epidermal nekrolyse). 
Sepsis* (often called "blood poisoning"), is a severe infection with whole-body inflammatory response, rapid swelling of the skin and mucosa (angioedema); blistering and peeling of the top layer of skin (toxic epidermal necrolysis); these side effects are rare (may affect up to 1 in 1,000 people) or of unknown frequency (toxic epidermal necrolysis) but are extremely serious and patients should stop taking the medicine and see their doctor immediately.
Hydroxypropylcellulose Lactosemonohydrat Magnesiumstearat Mannitol 
Lactose monohydrate Magnesium stearate Mannitol
- Tolucombi 80 mg/12,5 mg én gang dagligt er til patienter, hvis blodtryk ikke kan reguleres tilfredsstillende med telmisartan 80 mg. 
- Tolucombi 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 80 mg.
Knogler, led, muskler og bindevæv Ikke kendt: 
Musculoskeletal, connective tissue and bone disorders Not known: Weakness
Amantadin Thiazider kan øge risikoen for bivirkninger ved behandling med amantadin. 
Amantadine Thiazides may increase the risk of adverse reactions caused by amantadine.
- Medicin, der kan forhøje indholdet af kalium i blodet, såsom vanddrivende medicin, kaliumtilskud, saltsubstitutter som indeholder kalium og ACE-hæmmere (blodtrykssænkende medicin), ciclosporin (undertrykker kroppens immunforsvar) og andre lægemidler såsom heparinnatrium (blodfortyndende medicin) . 
- Medicines that may increase blood potassium levels such as potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, ACE inhibitors, cyclosporin (an immunosuppressant drug) and other medicinal products such as heparin sodium (an anticoagulant).
- Hypercalciæmi 
- Hypercalcaemia
Der er dog kun rapporteret om minimal eller ingen påvirkning ved den mængde thiazid (12,5 mg), som findes i Tolucombi. 
An increase in cholesterol and triglyceride levels has been associated with thiazide diuretic therapy; however, at the 12.5 mg dose contained in Tolucombi, minimal or no effects were reported.
- Tolucombi 80 mg/25 mg én gang dagligt er til patienter, hvis blodtryk ikke kan reguleres tilfredsstillende med Tolucombi 80 mg/12,5 mg eller til patienter, som tidligere er stabiliseret med telmisartan og hydrochlorthiazid hver for sig. 
- Tolucombi 80 mg/25 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Tolucombi 80 mg/12.5 mg or in patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Hver tablet indeholder 80 mg telmisartan og 25 mg hydrochlorthiazid. 
Each tablet contains 80 mg telmisartan and 25 mg hydrochlorothiazide.
Det frarådes at anvende Tolucombi i ammeperioden. 
The use of Tolucombi during breast feeding is not recommended.
Tolucombi 40 mg/12,5 mg tabletter Hver tablet indeholder 40 mg telmisartan og 12,5 mg hydrochlorthiazid. 
Tolucombi 40 mg/12.5 mg tablets Each tablet contains 40 mg telmisartan and 12.5 mg hydrochlorothiazide.
Tolucombi tidligt i graviditeten - se afsnittet ”Graviditet og amning”). 
(It is also better to avoid Tolucombi in early pregnancy-see pregnancy section.)
Psykiske forstyrrelser Ikke almindelig: 
Psychiatric disorders Uncommon: Anxiety Rare:
Lægemidler, som påvirkes af serumkaliumforstyrrelser Når Tolucombi anvendes sammen med lægemidler, hvis effekt påvirkes af serumkaliumforstyrrelser (såsom digitalisglykosider, antiarytmika) bør serumkalium og EKG monitoreres. 
Medicinal products affected by serum potassium disturbances Periodic monitoring of serum potassium and ECG is recommended when Tolucombi is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics) and the following torsades de pointes inducing medicinal products (which include some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes.
Tolucombi 80 mg/25 mg tabletter 
Tolucombi 80 mg/25 mg tablets
Tolucombi 80 mg/12,5 mg tabletter Hver tablet indeholder 80 mg telmisartan og 12,5 mg hydrochlorthiazid. 
Tolucombi 80 mg/12.5 mg tablets Each tablet contains 80 mg telmisartan and 12.5 mg hydrochlorothiazide.
Fastdosiskombinationen Tolucombi (80 mg telmisartan/25 mg hydrochlorthiazid) er indiceret til voksne, hvis blodtryk ikke kan reguleres tilfredsstillende med Tolucombi 80 mg/12,5 mg (80 mg telmisartan/12,5 mg hydrochlorthiazid) eller til patienter, som tidligere er stabiliseret med telmisartan og hydrochlorthiazid givet hver for sig. 
Tolucombi fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.